ETC-588 (Pfizer).
Pfizer, following its acquisition of Esperion Therapeutics in the first quarter of 2004, is developing ETC-588 as a potential acute treatment for ischemia caused by atherosclerosis. Enrollment in phase II trials in patients with acute coronary syndrome is complete.
Doggrell
Sheila A
SA
Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand. s.doggrell@xtra.co.nz
D000818:Animals; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy; D006801:Humans; D010713:Phosphatidylcholines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D002317:Cardiovascular Agents; D010713:Phosphatidylcholines; C034973:1-oleoyl-2-palmitoylphosphatidylcholine